Tuesday, November 9, 2021
9:00am – Live Stream
Welcoming Remarks
9:05am – 9:50am – Live Stream
It’s a New Dawn: How the World’s Leading Companies and Investors are Responding
Biotech is poised for another banner year in terms of investment. While the SARS-CoV-2 pandemic abruptly reordered global priorities over the last 18 months toward infectious diseases, vaccines, diagnostics, and healthcare delivery will these priorities continue or even expand in a post-pandemic world, and what does it mean to the broader emerging company sector as they pursue financing?
Moderator:
Jennifer Friel Goldstein, MBA, Managing Partner, Life Science and Healthcare, SVB Capital
Panelists:
- Stephen Curtis, PhD, Managing Director, MPM Capital
- Kim Kamdar, PhD, Partner, Domain Associates, LLC
- Marian Nakada, PhD, VP, Venture Investments, Johnson & Johnson Innovation – JJDC
- Denis Patrick, PhD, Vice President, WRDM, Head of Partnering Innovation, Pfizer, Managing Partner, Pfizer Ventures
9:00am – 10:00am – On Demand
Emerging Company Showcase
Session 1: Rumi Scientific, Pathovax, LLC, MenoGeniX, Medosome Biotec
Session 2: 3Helix, Inc., SomaGenics, Pelex
9:00am – 4:00pm
Partnering Forum Open for Meetings
10:00am – 10:45am – Live Stream
Innovation in the Time of Pandemic
Oncology Innovation continues unabated with new biology and targets being uncovered and novel therapeutic modalities being created it almost seems on a daily basis. Notwithstanding our tremendous advances in precision medicine and in immunotherapy, most cancer patients are not cured, especially for solid tumors, and these innovations remain desperately needed. Despite, or perhaps in part because of, the still ongoing pandemic, the past eighteen months has shown that the industry continued if not accelerated the intense level of focus in Oncology, from investment into startups to the number of partnerships, M&A and IPOs. This session will present some of these innovative companies, from the perspective of different senior executives, across Pharma, Biotech and Investors, to make for a well-rounded and lively discussion about the future trends in Oncology drug discovery and development.
Moderator:
Jeffrey M. Bockman, PhD, Executive Vice President, Oncology and Virology Practices, Cello Health BioConsulting
Panelists:
- Rachael Lester, MBA, SVP Corporate Strategy & Business Development, Harpoon Therapeutics
- Alana B. McNulty, MBA, Chief Business Officer, eFFECTOR Therapeutics
- Christopher Mortko, PhD, MBA, Associate VP, Business Development & Licensing, Merck Research Laboratories
- Anna Turetsky, PhD, Principal, Venture Investments, Mark Foundation
10:00am – 11:00am – On Demand
Emerging Company Showcase
Session 3: Avenzoar Pharmaceuticals, Escend Pharmaceuticals, Concarlo Holdings, Novomedix
Session 4: Quench Medical, Cayuga Biotech, CMTx Biotech
11:00am – 12:00pm – On Demand
Emerging Company Showcase
Session 5: Nervive, SoleStim, SeeTrue Technology
Session 6: NomoCan Pharmaceuticals, Early Diagnostics Inc., JBS Science, XenImmune
12:30pm – 1:30pm – Live Interactive Session
Investor and Partner Insights: Questions Asked and Answered
Driven by live audience questions, life science investors and strategic partners will share their insights about their process when contemplating an investment and inside tips on how to approach fundraising for your emerging life science company. The discussion will be followed by an open Q&A with companies seeking strategic partnerships, seed-stage and Series A financing.
Moderator:
William Burkoth, MBA, Managing Partner, Life Science & Healthcare, SVB Capital
Panelists
- Michael Baran, PhD, MBA, Partner, Pfizer Ventures, Executive Director, External Science & Innovation, Worldwide R&D, Pfizer, Inc..
- Olga Danilchanka, PhD, Principal, MRL Ventures Fund, Merck
- John Prufeta, Chairman & General Partner, Medical Excellence Capital, LLC
- Peter Young, MBA, Venture Partner, Pappas Capital
Wednesday, November 10, 2021
9:00am – Live Stream
Morning Remarks
9:00am – 9:50am – Live Stream
Emerging Sources of Capital in Global Health and National Health Security Markets
Global Health and Health Security have historically been the purview of government and not-for-profit agencies. However, there is now a growing trend toward corporate and venture investments in these markets as well. Emerging companies are evaluating whether it makes sense to pivot existing assets toward these applications and markets while others are wondering whether it’s strategically viable to jump in. Join our panel of experts who will help explore investment opportunities in the global health and health security markets.
Moderator:
Anton Xavier, MSc, MBA, Director, Startup Life Science Banking, Silicon Valley Bank
Panelists:
- Kara Cannon, Chief Commercialization Officer, Enzo Biochem Inc.
- Maria Mitchell, PhD, Sr. Vice President, Life Sciences, Empire State Development
- Sandeep Patel, PhD, Director, Division of Research, Innovation and Ventures, Biomedical Advanced Research and Development Authority
- Jenny Yip, Managing Partner, Adjuvant Capital
9:00am – 10:00am – On Demand
Emerging Company Showcase
Session 7: Axonis, Tellus Therapeutics, Obsidio, Inc., Jaan Biotherapeutics
Session 8: Hillhurst Biopharmaceuticals, Forkhead BioTherapeutics, Enalare Therapeutics Inc, Sen-Jam Pharmaceutical
Session 9: MarPam Pharma, SiVEC Biotechnologies, BriOri, Tu Therapeutics
9:00am – 4:00pm
Partnering Forum Open for Meetings
10:00am – 10:45am – Live Stream
Building and Financing an Early-Stage Bioscience Company
In the midst of the hype about record-breaking investment in biotech, it can be easy to forget that building and funding an early-stage bioscience company is still challenging – particularly during a pandemic! Join our experts as they discuss how to build an internal and external team that can attract and sustain the interest of investors and strategic partners.
Moderator:
Michael Glynn, PhD, Partner, Fox Rothschild LLP
Panelists:
- Laurence Blumberg, MD, President & CEO, Arch Oncology
- Matthew McMahon, PhD, Director, NIH SEED
- Harrison Seidner, PhD, Director, Business Development, Fortress Biotech
- Elizabeth Sigety, Partner, Fox Rothschild LLP, Managing Director & Co-Founder, Delaware Crossing Investor Group
10:00am – 11:00am – On Demand
Emerging Company Showcase
Session 10: ImmunogenX, Inc., Lohocla Research Corporation, MyoGene Bio, LLC, South Rampart Pharma
Session 11: Qx Therapeutics, Calder Biosciences, Inc., ENB Therapeutics
11:30am – 12:30pm Live Interactive Session
Investor and Partner Insights
Driven by live audience questions, life science investors and strategic partners will share their insights about their process when contemplating an investment and inside tips on how to approach fundraising for your emerging life science company. The discussion will be followed by an open Q&A with companies seeking strategic partnerships, and seed-stage and Series A financing.
Moderator:
Julie Wolf, PhD, Chief Science Officer, IndieBio
Panelists:
- Stephen Chambers, PhD, Managing Director, IndieBio and Partner, SOSV
- Anjali Kumar, PhD, External Innovation Search and Evaluation, East North America, Johnson & Johnson Innovation
- Jonathan Mandelbaum, PhD, Senior Associate, Orbimed
- Charles Petty, Co-founder and Principal, Adjuvant Capital